Vytorin for the Treatment of Hyperlipidemia
May 14, 2004 by admin · Leave a Comment
Vytorin is a combination therapy comprised of two drugs already separately approved for the treatment of hyperlipidemia. Zocor (simvistatin) and Zetia (ezetimibe) are combined in this oral medication currently awaiting an FDA decision on approval. Results released by Merck and Schering-Plough in March 2004 from Phase III clinical trials demonstrated that patients taking Zocor and [...]
Matritech’s NMP179 for Detection of Cervical Cancer
May 10, 2004 by admin · Leave a Comment
On May 10, 2004 Matritech announced the beginning of clinical testing of 10,000 samples by Sysmex Corporation using NMP179 for the detection of women at risk of or with cervical cancer. The company reported that this novel strategy uses both Sysmex’s flow cytometry technology and Matritech’s NMP179 protein biomarker to perform rapid, cell-by-cell analysis for [...]
Lorus Therapeutics GTI-2040 for Colon Cancer
May 4, 2004 by admin · Leave a Comment
On May 4, 2004 Lorus Therapeutics Inc. reported that it had initiated a clinical trial of GTI-2040 involving patients with advanced unresectable colon cancer. GTI-2040 was administered in combination with FDA approved chemotherapies capecitabine and oxaliplatin. Capectiabine is a first-line therapy while oxaliplatin is approved for use with 5 fluorouracil/ Leucovorin. This study is one [...]
Avanir Pharmaceuticals’ AVP 13358 for Asthma
May 3, 2004 by admin · Leave a Comment
On May 3, 2004 Avanir Pharmaceuticals released results of its Phase I clinical trial with AVP 13358 for asthma. The company reported that this trial, involving 54 healthy volunteers, was designed to demonstrate the safety, tolerability, and pharmacokinetic profile of a single oral administration of AVP 13358. The company indicated that AVP 13358 was well [...]